Who Optimizes SG&A Costs Better? Genmab A/S or Viridian Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Genmab A/S and Viridian Therapeutics, Inc. offer a fascinating study in contrasts over the past decade.

Genmab A/S: A Steady Climb

From 2014 to 2023, Genmab A/S saw its SG&A expenses rise significantly, peaking at a staggering 3.3 billion in 2023. This represents a growth of over 4,000% from its 2014 figures. Such an increase suggests aggressive expansion and investment in administrative capabilities.

Viridian Therapeutics, Inc.: A Conservative Approach

In contrast, Viridian Therapeutics, Inc. maintained a more conservative trajectory. Their SG&A expenses grew from 7.8 million in 2014 to 95 million in 2023, a more modest increase of approximately 1,100%. This indicates a more controlled approach to cost management.

Conclusion

While Genmab A/S's strategy reflects rapid growth, Viridian's approach suggests a focus on sustainable expansion. Both strategies have their merits, depending on the company's long-term goals.